Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling
Top Cited Papers
- 11 December 2007
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 104 (50) , 19936-19941
- https://doi.org/10.1073/pnas.0707498104
Abstract
Juice from the varieties Niagara, Delaware, and Catawba were clarified by: (1) settling 12 hours and racking and (2) pectolytic enzyme treatment and racking. For each variety, an unsettled and unracked juice was used as the control. All juices were fermented at 16.7°C with Saccharomyces cerevisiae Montrachet strain #522. Wines made from the unclarified juices tended to be higher in higher alcohol content. The methanol content was slightly higher in wines from the pectolytic enzyme-treated juices. Wines from the clarified juices were generally preferred by taste panelists to those from unclarified juices.Keywords
This publication has 20 references indexed in Scilit:
- MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 SignalingScience, 2007
- Molecular Predictors of Response to Epidermal Growth Factor Receptor Antagonists in Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2007
- A collection of breast cancer cell lines for the study of functionally distinct cancer subtypesCancer Cell, 2006
- Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysisBritish Journal of Cancer, 2006
- Gefitinib-Sensitizing Mutations in Esophageal CarcinomaNew England Journal of Medicine, 2006
- BRAF mutation predicts sensitivity to MEK inhibitionNature, 2005
- Phase II Study of Gefitinib in Patients with Relapsed or Persistent Ovarian or Primary Peritoneal Carcinoma and Evaluation of Epidermal Growth Factor Receptor Mutations and Immunohistochemical Expression: A Gynecologic Oncology Group StudyClinical Cancer Research, 2005
- KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or ErlotinibPLoS Medicine, 2005
- Addiction to Oncogenes--the Achilles Heal of CancerScience, 2002
- Mutations of the BRAF gene in human cancerNature, 2002